Operator
Good morning. My name is Ashley, and I ll be your conference operator today. At this time, I would like to welcome everyone to the Biogen s First Quarter Earnings Call and Financial Updates. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there will be a question-and-answer session. [Operator Instructions]
Thank you. I would now like to turn the conference over to Mr. Mike Hencke, Director, Investor Relations. Mr. Hencke, you may begin your conference.
Mike Hencke
Director of Investor Relations
Good morning, and welcome to Biogen s first quarter 2021 earnings call. Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the earnings release and related financial tables, including our GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today.
Billionaire Steve Cohen’s Top 10 Small-Cap Stock Picks
Steve A. Cohen is the owner of Point72 Asset Management, one of the most successful hedge funds in the U.S. He started off his Wall Street career as a junior trader at Gruntal & Co., where he dealt with options arbitrage. Cohen started his first hedge fund known as S.A.C. Capital Advisors in 1992, enjoying some success which allowed him to own 8 percent of Major League Baseball team, the New York Mets. He has also been involved in philanthropic causes in which he contributed $715 million.
Unfortunately, SAC Capital was allegedly involved in an insider trading scandal which led to a hefty $1.8 billion fine, and Cohen had to shut down the fund. This pave the way for the birth of his current hedge fund.
The FDA and U.S. Centers for Disease Control and Prevention (CDC) are recommending that U.S. states pause their administration of Johnson & Johnson’s Janssen COVID-19 Vaccine Candidate while they review six reported cases of patients developing what they termed rare and severe blood clots after receiving the vaccine.
The CDC’s Advisory Committee on Immunization Practices (ACIP) will meet Wednesday to review the cases and assess their potential significance. The FDA also plans to investigate those cases, and will review the CDC’s analysis, the agencies said this morning in a joint statement.
“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” the agencies said, in a statement by Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research and Anne Schuchat, MD, principal deputy director of the CDC and a retired rear admiral with the U.S. Public Health Service.
Moderna vs the Lobbyists: Who Has the Upper Hand? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.